Home / Resources / Articles / Use of Incretin-Related Medications Will Grow by 47 Percent

Use of Incretin-Related Medications Will Grow by 47 Percent

Oct 22, 2011
 

A new study found that the incretin-related medications will see the strongest growth among type 2 diabetes drugs over the next nine years.

DPP-IV inhibitors and GLP-1 drugs, two classes of drugs for treating type 2 diabetes will experience the biggest growth in market share of all classes of drugs for the condition, according to a new study.

 

The study found that DPP-IV inhibitors and GLP-1 analogues would experience the biggest growth in market share among all drug classes, with a combined market share that will increase from 20% in 2010 to 47% in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The report found that Merck & Co.’s Januvia (sitagliptin) dominates DPP-IV drugs and will consolidate its position, while GLP-1 analogues will have a strong position as well, with Novo Nordisk’s Victoza (liraglutide) having the opportunity to edge up due to delays in the launch of Bydureon (exenatide), a once-weekly GLP-1 analogue made by Eli Lily & Co., Amylin Pharmaceuticals and Alkermes.

Decision Resources report Oct. 2011